CytomX Therapeutics Gains Analyst Favor Ahead of Key Colorectal Cancer Data Release
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.